{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:55:29Z","timestamp":1792454129441,"version":"4.5.0"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:p>\n                    Cefiderocol may represent a therapeutic option for carbapenem-resistant\n                    <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii<\/jats:named-content>\n                    (CRAB) infections, but clinical data are limited. This is an observational retrospective study conducted in the University Hospital of Pisa including consecutive patients with CRAB infections (January 2020 to August 2021).\n                  <\/jats:p>","DOI":"10.1128\/aac.02142-21","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T09:31:11Z","timestamp":1647855071000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":190,"title":["Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-8796","authenticated-orcid":true,"given":"Marco","family":"Falcone","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Leonildi","sequence":"additional","affiliation":[{"name":"Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Della Sala","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vecchione","sequence":"additional","affiliation":[{"name":"Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Barnini","sequence":"additional","affiliation":[{"name":"Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Farcomeni","sequence":"additional","affiliation":[{"name":"Department of Economics and Finance, University of Rome \u201cTor Vergata,\u201d Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menichetti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organization. 2021. WHO publishes list of bacteria for which new antibiotics are urgently needed. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881200194X"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa530"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01643-4"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep17091"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.10.001"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx368"},{"key":"e_1_3_4_10_2","unstructured":"US Food and Drug Administration. 2019. Highlights of prescribing information: Fetroja (Cefiderocol). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209445s000lbl.pdf."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1410"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10060652"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02435-13"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz123"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab280"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0480-z"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00194-8"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.03.037"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00831-15"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00877-21"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-20"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2005.12.001"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.01.020"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis270"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-017-0199-8"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01663-0"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03013-2"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12716"},{"key":"e_1_3_4_30_2","unstructured":"CDC. 2021. CDC\/NHSN Surveillance Definitions for Specific Types of Infections. https:\/\/www.cdc.gov\/nhsn\/PDFs\/pscManual\/17pscNosInfDef_current.pdf."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.06.031"},{"key":"e_1_3_4_32_2","unstructured":"KDIGO. 2012. KDIGO clinical practice guideline for acute kidney injury. https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-AKI-Guideline-English.pdf."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2742-9"},{"key":"e_1_3_4_34_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MICs and zone diameters Version 11.0. http:\/\/www.eucast.org."},{"key":"e_1_3_4_35_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2021","unstructured":"CLSI. 2021. Performance standards for antimicrobial susceptibility testing. M100, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"31"},{"key":"e_1_3_4_36_2","unstructured":"FDA. 2021. FDA susceptibility test interpretive criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa586"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018174"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02142-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02142-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T09:07:58Z","timestamp":1652778478000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02142-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,17]]}},"alternative-id":["10.1128\/aac.02142-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02142-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"2021-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02142-21"}}